February is Black History Month, and here at PhRMA, we continue our decades-long commitment to reducing disparities in health care for minorities through developing and helping communities access innovative medicines and cures.
When we look at the African-American community in the United States, there are two diseases in particular where we have had great success in biopharmaceutical science resulting in longer, healthier lives: hypertension and HIV/AIDS.
The prevalence of high blood pressure (hypertension) in black Americans is among the highest in the world, and it is increasing. As a result, blacks have a 1.5-times greater rate of death attributable to heart disease than whites. Across the landscape of biopharmaceutical research, innovative medicines have had profound effects in reducing heart disease deaths by more than 30 percent over the last two decades – innovation that directly benefits those in the African-American community who do suffer from high blood pressure.
In the case of HIV and AIDS, it was not long ago that the disease claimed the lives of 72 African Americans each day. Today, safe and effective antiretroviral medications suppress the virus and prolong the lives of those living with HIV, turning what was once a death sentence into a manageable chronic disease. The National Institutes of Health reports that a person living with HIV on antiretroviral therapy can expect to live a nearly normal lifespan. With the virus suppressed, the chance of transmitting the disease is negligible. Those who are HIV negative are able to take a daily pill – PrEP (pre-exposure prophylaxis) – that helps prevent infection, and there is an HIV preventive vaccine currently in clinical trial. These innovations in medicine are remarkable in a disease that is only 35 years old and can inform how other infectious diseases are researched and treated through medications and therapies. As a result, we have seen the death rate from AIDS in the United States reduced by more than 70 percent, and in the African-American community specifically, the death rate per 1,000 persons living with HIV has decreased 28 percent between 2008 and 2012.
As we look ahead to the frontier of new prescription drug innovations to come, diabetes is one that stands to have a profound effect on the lives of African Americans. The American Diabetes Association reports that by the year 2050, one in three adults in the United States will have diabetes. African Americans are 70 percent more likely to have diabetes as compared to non-Hispanic Caucasians. We are excited about the 171 new medicines in development for type 1 and type 2 diabetes and related conditions such as chronic kidney disease, as well as the work many researchers are doing toward finding a cure.
This is all good news, but it’s not enough. We must work harder on eliminating regulatory hurdles so we can bring innovative cures and treatments to patients. We must ensure funding for basic, translational and clinical research on the front end to ease the burden on government programs and family finances on the back end. And we must ensure fair and equal access to care and quality of care for people of color.
We will continue our work with Congress and the administration on policies related to access to care that we know – and data shows – unfairly impact minority communities, including:
- Access to affordable health insurance;
- Rising costs of health insurance premiums;
- Rising costs of out-of-pocket health care expenses;
- Coverage for unplanned medical bills, especially hospital stays and ER visits;
- Affordability of and access to prescribed medications;
- Research addressing genetic differences in disease for African Americans; and
- Greater diversity and inclusion in clinical trials.
Black History Month is one month of the year, but PhRMA is committed to working with stakeholders to ensure these issues are highlighted year around. We honor this month as a time of reflection, respect and commitment to fair and equal access to health care, medicines and quality of life for the millions of patients across America who rely on medicine and therapies to survive and thrive.
Myisha Gatson
Myisha M. Gatson is former senior director of advocacy and strategic alliances for PhRMA.
Myisha Gatson
CMS’ MFN proposals won’t help seniors despite lofty promises
Voters voice concerns on government price controls
Health care practitioners sound the alarm on middlemen-imposed barriers to patient care, need for policy change
Three things to know about the United Nations’ new HIV/AIDS report
Case study: How seniors could face access disruptions because of the IRA’s price setting provisions
ICYMI: Misaligned policies undermine patient access
3 Takeaways from POLITICO’s Health Care Summit
American Heart Month: A nurse’s perspective
Watch: Putting patients front and center for World AIDS Day
New analysis of patient access restrictions in the United Kingdom
ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference
Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation
States can support access to medicine as COVID-19 Public Health Emergency ends
Recognizing National Glaucoma Awareness Month
Minnesota lawmakers are letting PBMs off the hook, and threatening patients’ access to medicines
In their own words: Insured Americans support policy reforms that address access and affordability concerns
Navigating the patient experience: Burdens and barriers standing between patients and their care
This week’s reading list: All the reasons the Senate-passed drug pricing bill is bad policy
Making coupons count for patients with HIV
Myth vs. Fact: The Senate’s latest price setting proposal
ICYMI: Patients across the country are sharing concerns about government price setting
New analysis finds deeper impact of drug pricing bill on biopharmaceutical researchers
ICYMI: A patient, physician, biotech investor and industry leaders warn about the dangers of government price setting bill
The Patient Perspective: Government price-setting harms patients
CMS coverage decision restricts access to treatments for Alzheimer’s disease
Report finds PBMs are increasingly restricting patient access to medicines
Spotlighting a growing mental health challenge
World AIDS Day: Remembering those we’ve lost and exploring the continued fight against HIV/AIDS
Insurance design barriers can impact patient adherence and can lead to poor health outcomes
Getting the 340B program back on track in 2021
Action needed to preserve the six protected classes
Study finds biopharmaceutical innovation is responsible for 35% of the increase in life expectancy from 1990 to 2015
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
Growth in innovative, value-based contracts holds promise for the health system and for patients
Innovative contracts drive access for patients and value for the system
Commercial health plans have increased patients’ out-of-pocket costs by over 50% in some therapeutic areas
ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements
PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs
Addressing barriers that inhibit value-based contracts
New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country
Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important
Setting the record straight on international reference pricing
Fact Check: How the Part B International Pricing Index model threatens patient access
New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid
Changes to the six protected class policy are the wrong prescription for Medicare and HIV patients
PhRMA comments to administration on Medicare Part D proposed rule
Keep the Six Protected Classes, protected
ICYMI: New study reinforces dangers of proposed IPI model
World AIDS Day 2018: Hope for the future
Groups sound the alarm on administration’s new Part B proposal
4 things you need to know about the administration’s latest Part B proposal
PhRMA submission to the 2019 National Trade Estimate Report urges action to protect U.S. biopharmaceutical innovation
What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?
How much do you know about Medicare Part B?
ICER’s budget impact threshold: Sounding a false alarm on affordability and access
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
Event next week: Supporting the next generation of lifesaving medicines
How ICER’s assessment of a new class of migraine treatments fails patients
Guest post: Excellent care for LGBTQ patients requires cultural humility and specific medical knowledge
Diversity of thought fuels next generation of breakthroughs
New analysis shows that more medicines worldwide are available to U.S. patients
New analysis shows that HTA organizations may frequently restrict access to cancer treatments
New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B
Event tomorrow: Improving patient access to lifesaving medicines
New 340B analysis: Hospitals raking in billions while uncompensated care drops by billions
Event tomorrow: Making the biopharmaceutical supply chain work for patients
New report shows over 500 medicines in development for neurological disorders
PPA celebrates 13 years of helping patients access their medicines
Copay coupons can help ease patients’ out-of-pocket costs
Fact Check Friday: The truth about the cost of 340B to patients
PhRMA launches new consumer-facing Let’s Talk About Cost website
340B Spotlight: New pieces of legislation continue momentum to fix 340B program
World AIDS Day 2017: Scientific breakthroughs paving the way for an AIDS-free generation
Video: What is a results-based contract?
340B Spotlight: ICYMI – 340B hearing, new reports highlight growing need for program reform
How much are hospitals marking up the price of medicines? The answer may surprise you.
VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria
Protect your health: Important disaster preparedness tips for Harvey and Irma
More than 50 medicines and vaccines in development for HIV infection, treatment and prevention
Foreign government price setting by any name harms innovation and access to medicines
Compulsory licensing: A misused and abused international trade law
ICYMI: New study shows medicines advance life expectancy for HIV patients
Government-imposed price controls threaten innovation and access
Medicare Monday: A discussion on affordability and access to medicines
17 years (and more) of medical discoveries
How do multiple sclerosis patients define value?
ICYMI: New era of medicine initiative kicks off in Boston
Medicare Monday: What is IPAB, and why is it bad for patients?
Medicare Monday: How Part D helps patients with heart disease live longer, healthier lives
Biopharmaceutical industry’s success reducing disparities for African Americans
Access
Heart Disease
HIVAIDS
Patients
Biopharmaceutical industry’s success reducing disparities for African Americans
Biopharmaceutical industry’s success reducing disparities for African Americans